The company's focus is on commercialization of off-patent drugs, in large markets, where product safety and efficacy can benefit significantly by improving delivery and market entry can be accomplished in 3-5 years. The first product under development will be the most rapid sedative treatment for patients presenting with acute agitation and aggression in hospitals and emergency department which threatens the safety of the patient and staff.